Replimune Group (NASDAQ:REPL) Insider Sells $65,956.80 in Stock

Replimune Group, Inc. (NASDAQ:REPL) insider Konstantinos Xynos sold 7,248 shares of the stock in a transaction on Monday, November 17th. The stock was sold at an average price of $9.10, for a total transaction of $65,956.80. Following the transaction, the insider owned 139,685 shares in the company, valued at approximately $1,271,133.50. This trade represents a 4.93% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

Replimune Group Stock Performance

Shares of NASDAQ REPL traded up $0.25 during trading hours on Wednesday, hitting $8.99. 1,895,576 shares of the stock were exchanged, compared to its average volume of 4,388,618. The company has a debt-to-equity ratio of 0.26, a current ratio of 6.31 and a quick ratio of 6.31. The company’s 50 day moving average is $6.56 and its 200 day moving average is $7.39. The firm has a market capitalization of $705.18 million, a P/E ratio of -2.60 and a beta of 0.80. Replimune Group, Inc. has a one year low of $2.68 and a one year high of $17.00.

Replimune Group (NASDAQ:REPL) last issued its quarterly earnings results on Thursday, November 6th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.87) by ($0.03). On average, research analysts expect that Replimune Group, Inc. will post -2.97 EPS for the current year.

Hedge Funds Weigh In On Replimune Group

Institutional investors and hedge funds have recently modified their holdings of the stock. Scientech Research LLC bought a new position in shares of Replimune Group in the third quarter valued at about $102,000. Fcpm Iii Services B.V. grew its stake in Replimune Group by 6.4% in the 3rd quarter. Fcpm Iii Services B.V. now owns 4,158,368 shares of the company’s stock valued at $17,424,000 after buying an additional 248,672 shares during the last quarter. Braidwell LP raised its holdings in Replimune Group by 550.3% in the 3rd quarter. Braidwell LP now owns 2,750,092 shares of the company’s stock valued at $11,523,000 after acquiring an additional 2,327,205 shares during the period. Alliancebernstein L.P. lifted its position in Replimune Group by 23.4% during the third quarter. Alliancebernstein L.P. now owns 63,540 shares of the company’s stock worth $266,000 after acquiring an additional 12,050 shares during the last quarter. Finally, Raymond James Financial Inc. boosted its holdings in shares of Replimune Group by 2,422.2% during the third quarter. Raymond James Financial Inc. now owns 186,994 shares of the company’s stock worth $784,000 after acquiring an additional 179,580 shares during the period. 92.53% of the stock is currently owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several research analysts have recently issued reports on REPL shares. BMO Capital Markets lowered Replimune Group from an “outperform” rating to an “underperform” rating and reduced their price target for the stock from $27.00 to $2.00 in a research report on Wednesday, July 23rd. Leerink Partnrs upgraded shares of Replimune Group from a “hold” rating to a “strong-buy” rating in a report on Monday, October 20th. Weiss Ratings reissued a “sell (e+)” rating on shares of Replimune Group in a research report on Monday. Cantor Fitzgerald upgraded shares of Replimune Group from a “neutral” rating to an “overweight” rating in a research note on Wednesday, July 30th. Finally, Piper Sandler raised Replimune Group from a “neutral” rating to an “overweight” rating and set a $13.00 price objective for the company in a report on Monday, October 20th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, two have issued a Hold rating and two have assigned a Sell rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $9.75.

About Replimune Group

Replimune Group, Inc, a clinical-stage biotechnology company, focuses on the development of oncolytic immunotherapies to treat cancer. The company's proprietary tumor-directed oncolytic immunotherapy product candidates are designed and intended to activate the immune system against cancer. Its lead product candidate is RP1, a selectively replicating version of HSV-1 that expresses GALV-GP R(-) and human GM-CSF, which is in Phase I/II clinical trials for a range of solid tumors; and that has completed Phase II clinical trials for treating cutaneous squamous cell carcinoma.